← Product Code [JWH](/productcode/JWH) · K991143 # MAGNA-ROM 21 KNEE SYSTEEM (K991143) _Sulzer Orthopedics, Inc. · JWH · Jun 11, 1999 · Orthopedic · SESE_ **Canonical URL:** https://fda-staging.innolitics.com/device/K991143 ## Device Facts - **Applicant:** Sulzer Orthopedics, Inc. - **Product Code:** [JWH](/productcode/JWH.md) - **Decision Date:** Jun 11, 1999 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 888.3560 - **Device Class:** Class 2 - **Review Panel:** Orthopedic - **Attributes:** Therapeutic ## Indications for Use The Magna-ROM 21 Knee System is intended for replacement of the knee joint during total knee arthroplasty. Components of the Magna-ROM system are intended for use only with bone cement. Specific diagnostic indications include: 1. Patient conditions of inflammatory degenerative joint disease (e.g., rheumatoid arthritis). 2. Patient conditions of noninflammatory degenerative joint disease (e.g., osteoarthritis, avascular necrosis). 3. Correctable valgus-varus deformity and moderate flexion contracture. 4. Those patients with failed previous surgery where pain, deformity or dysfunction persists. 5. Revision of previously failed knee arthroplasty. ## Device Story Magna-ROM 21 Knee System is a total primary knee prosthesis designed for Asian patient anatomy; features smaller anterior/posterior depth and larger medial/lateral width compared to conventional components. System includes cast CoCr alloy femoral component with porous CSTi coating; cast Ti-6Al-4V alloy tibial baseplate with wing-shaped keel and CSTi coating; and polyethylene tibial inserts (cruciate-supplementing or cruciate-sparing). Patella prosthesis is all-polyethylene. Device implanted by orthopedic surgeons during total knee arthroplasty; requires bone cement for fixation. Design facilitates range of motion up to 135° (cruciate-sparing). Provides proportional fit for smaller adult sizes; enhances contact area via rounded condylar geometry. Benefits include improved anatomical fit, stability, and restoration of joint function. ## Clinical Evidence Bench testing only. No clinical data provided. Stability evaluated via tibiofemoral and patellofemoral constraint testing per Greenwald et al. Tibial baseplate fatigue and insert attachment strength compared to commercially available devices. ## Technological Characteristics Materials: Cast CoCr alloy (femoral), Ti-6Al-4V alloy (tibial baseplate), polyethylene (inserts/patella). Porous coating: Cancellous Structured Titanium (CSTi). Design: Total condylar, semi-constrained. Fixation: Cemented only. Connectivity: None. Software: None. Sterilization: Not specified. ## Regulatory Identification A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027). ## Predicate Devices - Sulzer Orthopedics Natural-Knee II System - Apollo Knee System ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ ## K99 1147 510(k) SUMMARY In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CFR 807, this is to serve as a Summary of Safety and Effectiveness for the Sulzer Orthopedics® Magna-ROM™ 21 Knee System. | Submitter: | Sulzer Orthopedics Inc.
9900 Spectrum Drive
Austin, Texas 78717
(512) 432-9900 | | |-------------------------|------------------------------------------------------------------------------------------------------------|--| | Date: | April 1, 1999 | | | Contact Person: | Mitchell A. Dhority
Manager, Regulatory Affairs | | | Classification Name: | Prosthesis, knee, patellofemorotibial, semi-constrained
cemented, polymer/metal/polymer 21 CFR 888.3560 | | | Common/Usual Name: | Knee Prosthesis, Partially Constrained | | | Trade/Proprietary Name: | Magna-ROM™ 21 Knee System | | ### SPECIFIC DIAGNOSTIC INDICATIONS The Magna-ROM 21 Knee System is intended for replacement of the knee joint during total knee arthroplasty. Specific diagnostic indications include: - 1. Patient conditions of inflammatory degenerative joint disease (e.g., rheumatoid arthritis). - 2. Patient conditions of noninflammatory degenerative joint disease (e.g., osteoarthritis, avascular necrosis). - 3. Correctable valgus-varus deformity and moderate flexion contracture. - Those patients with failed previous surgery where pain, deformity or dysfunction persists. 4. - Revision of previously failed knee arthroplasty. 5. Components of the Magna-ROM system are intended for use only with bone cement. ## PRODUCT DESCRIPTION The Magna-ROM 21 Knee System is a total primary knee system that was designed to provide a better proportional fit for people of Asian descent. Studies of Japanese and Chinese anatomy have shown that the shape of the knee is slightly different than the European or American knee, particularly in the smaller adult. Results of a study in which Sulzer Orthopedics examined CT-scan data from 52 Japanese patients showed that the anterior/posterior depth is smaller for the Asian knee as compared to the American or European knee, and the medial/lateral width is larger. Components of the Magna-ROM 21 Knee System are basically the same as conventional knee components. However, based on the data collected from the CT-Scan study, dimensions of the Magna-ROM components were scaled to address those patients who exhibit the need (through preoperative templating) for somewhat wider mediolateral coverage and smaller {1}------------------------------------------------ anteroposterior coverage than conventional knee components can provide. The size range for the Magna-ROM system also includes proportionally smaller components than conventional knee components because of the smaller adult sizes in the Asian population. The design features for each Magna-ROM component are described below. ### Femoral Component The femoral component is a total condylar prosthesis that is manufactured from cast CoCr alloy. It has an anatomical design and will be offered in five sizes in both left and right configurations. The interior box of the femoral component is porous coated with Sulzer Orthopedics™ Cancellous Structured Titanium™ (CSTi™) for potentially enhanced cement fixation. The femoral component incorporates a deep patellar groove that conforms to the geometry of the patella prosthesis and provides for rolling/sliding articulation. The condylar geometry is rounded in both the anterior/posterior and medial/lateral planes to enhance contact area with the polyethylene tibial insert. The posterior condyles are slightly longer than conventional femoral components to facilitate optimum range of motion. #### Tibial Component The tibial component consists of a metal baseplate that is manufactured from cast Ti-6Al-4V alloy that is used in conjunction with a snap-in polyethylene insert. The tibia component is a symmetric design, eliminating the need for left and right configurations. The tibia baseplate will be offered in five sizes and has a wing-shaped keel for enhanced fixation within the intramedullary canal. Rotational stability is provided by two posterior fixation pegs. The underside of the baseplate, with the exception of the keel, is porous coated with CSTi for potentially enhanced cement fixation. Two screwholes are provided for the possible use of bone screws, if desired by the surgeon. Tibial inserts will be offered in four thicknesses (6mm to 13mm) for each size and are designed with a snap-lock mechanism for attachment to the baseplate. The insert comes in two styles, both of which are designed to preserve the posterior cruciate ligament PCL. The cruciate supplementing design is for those patients with a weaker PCL and/or soft tissue laxity. Resistance to anterior and posterior subluxation is supplied by a moderately constraining surface geometry. This design yields up to 120° of flexion, as determined by CAD kinematic overlay analysis. The cruciate sparing design will be used for those patients with good ligament support. This style has slightly larger posterior radii. This, along with the longer posterior condyles of the femoral component, facilitates a larger range of motion (up to 135° of flexion). #### Patella The patella prosthesis is a cemented all-polyethylene component and comes in two styles: a round patella, which is recessed in the bone, and an offset patella, which utilizes a surface technique. The offset patella is slightly elliptical in shape and the crest is medial of center to more closely replicate the natural anatomy. Three sizes of each style will be available and may be matched with any size femoral component. {2}------------------------------------------------ ## SUBSTANTIAL EQUIVALENCE The Magna-ROM 21 Knee System is substantially equivalent to Sulzer Orthopedics Natural-Knee II System and Apollo Knee System. The stability of the Magna-ROM 21 Knee components was determined by evaluating tibiofemoral and patellofemoral constraint. Testing showed that this design provides adequate constraint when subjected to shear forces experienced by the knee as established by Greenwald et al. Tibial baseplate fatigue and insert attachment strength were evaluated and found to be comparable to a commercially available device. {3}------------------------------------------------ Image /page/3/Picture/1 description: The image is a black and white circular logo. The logo contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter of the circle. In the center of the circle is a stylized image of an eagle or other bird with three curved lines representing its wings or feathers. The overall design is simple and conveys a sense of official government branding. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 JUN 11 1999 Ms. Shavawn Evans Parduhn Requlatory Affairs Specialist Sulzer orthopedics Inc. 9900 Spectrum Drive Austin, Texas 78717 Re : K991143 Trade Name: Magna-Rom™ 21 Knee System Requlatory Class: II Product Code: JWH Dated: April 2, 1999 Received: April 5, 1999 Dear Ms. Parduhn: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). This decision is based on this device being equivalent only to similar devices labeled and intended to be fixed within bone with acrylic "bone You may, therefore, market your device subject to cement." the general controls provisions of the Act and the following limitations: - 1. The thinnest tibial insert available is the nominal "Size 00/0, 9mm" insert, which has a minimum polyethylene thickness under the condyles of 6.0mm. - 2. This device may not be labeled or promoted for noncemented use. - 3 . All labeling for this device, including package label and labeling included within the package, must prominently state that the device is intended for cemented use only. {4}------------------------------------------------ Page 2 - Ms. Shavawn Evans Parduhn - Any non-cemented fixation of this device is considered 4 . investigational and may only be investigated as a significant risk device in accordance with the investigational device exemption (IDE) regulation under All users of the device for non-21 CFR, Part 812. cemented fixation must receive approval from their respective institutional review boards (IRBs) and the Food and Drug Administration (FDA) to conduct the investigation. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practices, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. ਜੋ substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Reqister. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Requlations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification immediately. An FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. If you desire specific advice for your device on our labeling requlation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be {5}------------------------------------------------ Page 3 - Ms. Shavawn Evans Parduhn obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours, G. Celia M. Witten, Ph.D., M. a M. Witten, Ph.D., M.D. Celi Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {6}------------------------------------------------ Page 1 of 1 510(k) Number (if known): K99114 Device Name: Magna-ROM™ 21 Knee System # Indications For Use: The Magna-ROM 21 Knee System is intended for replacement of the knee joint during total knee arthroplasty. Components of the Magna-ROM system are intended for use only with bone cement. Specific diagnostic indications include: - 1. Patient conditions of inflammatory degenerative joint disease (e.g., rheumatoid arthritis). - 2. Patient conditions of noninflammatory degenerative joint disease (e.g., osteoarthritis, avascular necrosis). - 3. Correctable valgus-varus deformity and moderate flexion contracture. - Those patients with failed previous surgery where pain, deformity or dysfunction persists. 4. - 5. Revision of previously failed knee arthroplasty. (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) | | protepa | |--|---------| | | K991143 | | Prescription Use |
Yes
| OR | Over-The-Counter Use |
No
| |------------------|---------------------------------------------------------------------|----|----------------------|--------------------------------------------------------------------| |------------------|---------------------------------------------------------------------|----|----------------------|--------------------------------------------------------------------| (Optional Format 1-2-96) --- **Source:** [https://fda-staging.innolitics.com/device/K991143](https://fda-staging.innolitics.com/device/K991143) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com